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Background: Oral iron supplementation is commonly used to treat 
and prevent anaemia. The transmembrane protease serine 6 gene (
TMPRSS6), which encodes matriptase 2, is a negative regulator of 
hepcidin, the key controller of iron homeostasis. Genome-wide 
association studies (GWAS) have identified several single nucleotide 
polymorphisms (SNPs) in the TMPRSS6 gene that are associated with 
an increased risk of iron-deficiency anaemia.  We will investigate the in 
vivo effects of three previously reported TMPRSS6 variants (rs855791, 
rs4820268 and rs2235321) on oral iron absorption in non-anaemic 
volunteers in The Gambia. 
Methods: A recall-by-genotype study design will be employed. Pre-
genotyped participants will be recruited from the West African 
BioResouce (WABR), which currently contains over 3000 genotyped 
individuals. Male and female volunteers will be selected based on 
polymorphisms (rs855791, rs4820268 and rs2235321) in the TMPRSS6 
gene in the Gambian population. The effects of a single variant allele 
at one SNP and the additive effect of two or three variant alleles from 
either two or all three SNPs will be investigated. Study participants will 
be given a single oral dose of 400mg ferrous sulfate, and blood 
samples will be collected at baseline, two hours and five hours post 
supplementation. Differences in iron absorption between genotype 
groups will be assessed by measuring the increase in serum iron 
concentration at five hours post iron ingestion. 
Discussion: This study will increase understanding of the role of 
genetic variations in TMPRSS6 on oral iron absorption in subjects of 
West African origin. This will test for the biological basis for the 
association of each of the three TMPRSS6 variants with iron 
absorption. This may help in guiding future iron intervention 
strategies, particularly in populations with a high frequency of these 
SNPs and a high frequency of anaemia. 
Study registration: ClinicalTrials.gov NCT03341338 14/11/17.
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Introduction
Despite aggressive implementation of iron supplementation 
programs, either alone or in combination with food-based 
supplementation, the prevalence of anaemia remains high in 
low- and middle-income countries1,2. The World Health 
Organisation (WHO) has set 2050 as a target date by which the 
current anaemia burden will be reduced by half. In order to 
achieve this goal, it will be important to identify the major 
drivers of anaemia.
The transmembrane protease serine 6 gene (TMPRSS6), which 
encodes for matriptase-2, is one of the negative regulators of 
hepcidin3, the key iron homeostasis regulator4. When serum 
iron levels are low, matripase-2 suppresses hepcidin expression, 
allowing more iron from the diet to be absorbed through the 
intestines into the bloodstream5,6. A single nucleotide poly-
morphism (SNP) in the TMPRSS6 gene can lead to decreased 
expression or inactivation of matripase-27, which would then 
lead to inappropriately elevated hepcidin levels, inhibited iron 
absorption and would thereby result in an increased risk of 
anaemia5.
Multiple SNPs in the TMPRSS6 gene have been linked to 
iron-refractory iron deficiency anaemia (IRIDA), a hereditary 
anaemia that is not responsive to oral iron supplementation8. In 
addition, many SNPs in TMPRSS6 (including rs855791, rs4820268 
and rs3345321) have been linked to an increased risk of iron 
deficiency anaemia (IDA) in genome-wide association studies 
(GWAS)9–11. In Caucasian populations, rs855791 has been 
reported to be in strong linkage disequilibrium (LD) with 
rs4820268 (r2=0.83) and rs2235321 (r2=0.44)12. Similarly, in 
Asian populations, rs855791 is reported to be in high LD with 
rs4820268 (r2=0.65)12. 
The minor allele frequency (MAF) of these SNPs varies between 
racial and ethnic groups. In African populations, the MAF of 
rs855791 is lower (10%) than in East Asians (57%), South 
Asians (54%) and Europeans (39%)13. Similarly, the MAF of 
rs4820268 is lower in Africans (28%) compared to Europe-
ans (42%), whereas, the MAF of rs2235321 in Africans (41%) 
is similar to that of the European population (42%)13. The 
effects of these SNPs (rs855791, rs4820268 and r2235321) 
on iron absorption and hepcidin levels in Subsaharan African 
populations has not been studied.
We hypothesize that these genetic variants and similar ones 
in iron regulatory genes may contribute to the high anaemia 
prevalence in sub-Saharan Africa. Here, we propose to inves-
tigate effects of these three TMPRSS6 SNPs on oral iron 
absorption in Gambian adults.
We anticipate that this study will provide a biological insight 
into the association of these three TMPRSS6 variants with 
anaemia.
Protocol
Study objectives and outcome measures
The primary objective of this study is to assess the impact of 
single and multiple copies of variant alleles of the TMPRSS6 
SNPs (rs855791, rs4820268 and rs2235321) on oral iron 
absorption. The primary outcome measure will be the change 
in serum iron concentration before and five hours after a single 
400 mg dose of ferrous sulfate iron given orally (Figure 1).
Secondary endpoints related to the primary objective are:
(1)    Increase in transferrin saturation (TSAT) above baseline 
after a single oral 400 mg dose of ferrous sulfate iron.
(2)    Increase in serum unbound iron binding capacity (UIBC) 
above baseline after a single oral 400 mg dose of ferrous sul-
fate iron.
(3)    Increase in serum hepcidin levels above baseline after a 
single oral 400 mg dose of ferrous sulfate iron.
(4)    Ferritin, haemoglobin, mean corpuscular volume (MCV) and 
soluble transferrin receptor (sTFR) at baseline, as measures of 
iron status.
(5)    White blood cell count (WBC), granulocyte count, C-reactive 
protein (CRP) and alpha-1-acid glycoprotein (AGP) at base-
line, as measures of the inflammatory state.
           Amendments from Version 1
Version 2 contains modifications that were made in response to 
the independent reviews.
Introduction:
The statement “and may partially be responsible for 
disproportionately high anaemia prevalence in sub-Saharan 
Africa” has now been changed to “these and other genetic 
variations may contribute to the high anaemia prevalence in sub-
Saharan Africa”.
Methods
The manuscript has been modified to indicate that:
(1) data on weight and height will be collected and BMI will be 
included as a variable in the analysis.
(2) Participants will be informed to fast overnight (minimum  
12 hours) before sample collection.
(3) Sickle cell and G6PD status will be assessed in the subjects.
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Figure 1. Time line showing oral iron absorption test.
(6)    Sickle cell haemoglobin and glucose 6-phosphatase deficiency 
(G6PD) status at baseline to assess potential confounding 
effects of these two genetic conditions, which are common in 
this population.
Study design
We will employ a recall-by-genotype study design, in which 
participant selection will be based on TMPRSS6 SNPs reported 
to be associated with the risk of iron-deficiency anaemia: 
rs855791, rs4820268 and rs223532110,14,15. We will utilize the 
West African BioResouce (WABR), which contains the Kiang 
West Longitudinal Population Study (KWLPS) as the basis 
for selection of pre-genotyped participants16.
Study site
The proposed study will be conducted within the population 
of West Kiang (WK) District, in the Lower River Region of 
The Gambia, and study procedures will be conducted at the 
Medical Research Council The Gambia (MRCG) at London 
School of Hygiene & Tropical Medicine (LSHTM), Keneba 
Field Station16. Individuals that are eligible for the study 
but have moved to the coastal region of The Gambia will be 
followed-up by a fieldworker and study procedures will be 
conducted at the MRCG Fajara site. Participants currently residing 
in WK will be prioritised.
Participants
A total of 300 participants (male and female) will be recruited. 
Participants will be chosen based on three TMPRSS6 SNPs 
(rs855791, rs4820268 and rs2235321), from which we will 
generate nine genotype combinations, as detailed in Table 1. This 
will allow the investigation of the effect of each SNP individually 
and in combination. Composite genotype group 3 is the control 
group with no variant alleles. Due to the low MAF of rs855791 
in our study population, we are unable to include homozygotes 
for the variant allele. This limited the selection of genotype 
combinations, and only nine combinations had sufficient 
participants to include in the study.
For inclusion, participants must be 18 years and above, in 
good physical health, have available genotype data, be able 
to fast overnight prior to the study visit and be able to give 
informed consent. Individuals will be excluded from the study 
if they have any signs of infection at the time of enrolment, 
are severely anaemic (Hb <7 g/dl), pregnant or breastfeeding, or 
have a positive malaria test at screening.
Sample size calculation
The total sample size will be 300. This will include approximately 
62 wild type subjects and an average of 31 in each of the eight 
variant genotype groups. This study size will be able to detect 
a 12% mean difference in serum iron at five hours after oral 
iron supplementation between the wild type and the variant 
genotype groups with 90% power and a type 1 error of 0.1 in 
this study.
Study procedures
Potential participants with the candidate composite genotypes 
of interest will be selected from the study database by the prin-
cipal investigator, and contact details (including address and 
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phone number) will be extracted from the WK Demographic 
Surveillance System16 by the study data manager. Participants will 
be contacted either in person or by telephone. Participants who 
provide informed consent will be invited to the study site 
where the rest of the study procedures will be conducted, as 
summarised in Figure 2. Each participant will be instructed to 
fast overnight for a minimum of 12 hours and then will donate 
a blood sample on arrival to the clinic. Weight and height 
measurements will be done to be used for calculating body 
mass index (BMI).
Each participant will be given a single dose of 400mg ferrous 
sulfate oral iron (2x 200mg ferrous sulfate tablets), equiva-
lent to 130mg elemental iron. To ensure that the iron tablets 
are taken, a nurse will observe and record the time injestion. 
Participants will be asked to stay at the study site until the 






















AA/GG/AA A/A G/G A/A 2 570
AG/GG/GA A/G G/G G/A 2 687
GG/GG/AA G/G G/G A/A 0 199
GG/GG/GA G/G G/G G/A 1 386
GG/GG/GG G/G G/G G/G 2 161
AG/AG/AA A/G A/G A/A 2 132
AG/GG/AA A/G G/G A/A 1 632
GG/AG/AA G/G A/G A/A 1 104
GG/AG/GA G/G A/G G/A 2 98
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study is completed, which is after collecting the five hour post 
supplementation blood sample (Figure 1).
All data generated from this study will be anonymised by 
allocating a unique study ID to each participant. Screening, 
enrolment and sample collection details will be collected in 
standard study forms and entered into the study database. Data 
will be double-entered by two data entry clerks and verified by a 
data supervisor.
In order to prevent bias in treatment, the composite genotype 
of individuals will not be disclosed to the study team (data 
management, field and clinical staff). In addition, participants 
will be recruited in groups at random, and individuals with 
different composite genotype groups will be mixed during study 
visits.
Sample collection
A 3ml whole blood sample will be collected at baseline. 
2.5ml will be collected in lithium heparin tubes. 500µl will be 
collected in EDTA (ethylenediaminetetraacetic acid) micro tubes 
to be used for full blood count (FBC), malaria rapid testing and 
sickle screening.
Post supplementation blood samples (3ml blood sample in 
lithium heparin tube) will be collected at two hours and five 
hours following iron ingestion. Pre- and post-supplementation 
blood samples in lithium heparin tubes will be spun and the 
plasma aliquoted in barcode-labelled tubes and stored at -20°C for 
iron biomarker analysis.
Laboratory analyses
FBC will be analysed using a 3-part haematology analyser 
(Medonic M-series, Boule Medical, Sweden). Iron biomark-
ers [serum iron, unsaturated iron binding capacity (UIBC), fer-
ritin, soluble transferrin receptor (sTfR), haptoglobin (HP)] and 
inflammatory markers [C-reactive protein (CRP) and alpha-1-acid 
glycoprotein (AGP)] will be measured using a Cobas Integra 
400 plus biochemistry analyser (Roche Diagnostics). Total iron 
binding capacity and transferrin saturation of iron (TSAT) will 
be calculated from serum iron and UIBC. Plasma hepcidin levels 
will be measured using a commercially available ELISA (DRG 
Instruments GmbH, Germany). The sickle rapid test will be 
analysed using the sodium metabisulphide method and posi-
tive samples will be genotyped by Hb electrophoresis. G6PD 
deficiency will be assessed using a qualitative enzyme assay 
(G6PD Hb+ R&D Diagnostics). Individuals carrying these 
variants will be excluded from the analysis if this will not 
significantly reduce the sample size. Otherwise, a retrospective 
sensitivity analysis will be done to assess the impact of these 
variants.
Statistical analysis plan
Primary analysis will be to assess the change in serum iron 
between the composite genotype groups at the five hours post- 
supplementation time point. A linear model will be fitted with 
genotype group as the independent variable and serum iron or 
TSAT as response variables and genotype group as the 
main predictor, with the inclusion of age, sex, inflamma-
tion status (CRP and AGP levels) and BMI as covariates. 
Using the same approach, we will also examine the effect of 
genotype on secondary outcome measures. The baseline iron 
level of the participants may vary. All secondary analysis are 
exploratory.
In order to remove this potential source of bias, we will adjust 
for baseline serum iron in the regression analysis. If the missing 
data rate is more than 5%, we will consider imputation. The 
follow-up duration is short; thus, we expect little bias from loss 
to follow-up. We will also consider sensitivity analysis, fitting 
a multivariate regression model where the main outcomes of 
interest (including TSAT, iron and hepcidin) will be jointly 
regressed to the same set of predictors.
Ethical statement
This study has been approved by the MRC Unit The Gambia at 
the LSHTM Scientific Coordinating Committee, MRC Unit 
The Gambia at the LSHTM / Gambia Government Joint Ethics 
Committee (SCC1429), and the LSHTM Ethics Committee 
(LSHTM Ethics reference number 11679). A trained field 
worker will visit each potential study participant to issue an 
information sheet detailing the purpose and nature of the 
study (see Extended data)17. Individuals who cannot read will 
have the information sheet translated into a language they 
understand by the fieldworker, in presence of an independent 
witness. Furthermore, participants will be given the opportunity 
to ask questions to the investigators that they deem important. 
Participants will be informed that they are free to withdraw 
from the study anytime, and they can further raise any question 
about the study with the investigators.
Participants will provide written informed consent, and those who 
cannot write will provide a thumbprint prior to enrolling into the 
study. Confidentiality of study participants will be protected by 
anonymising all study samples and forms by allocating a study 
number to each participant.
This study was retrospectively registered with ClinicalTrials.gov 
(NCT03341338) on 14th November 2017.
Dissemination of information
The study results will be published in relevant peer-reviewed 
journals and key findings will be presented at international 
scientific meetings. Data sharing will be in agreement with the 
MRC policy on research data sharing.
Study status
The study is in the data collection phase at the time of publication.
Discussion
GWAS has identified several genetic variants associated 
with iron status3,11,15,18–20. However, detailed understanding of 
genotype-phenotype relationships is required to identify their 
effects on iron absorption. The recall-by-genotype (RbG) 
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study design is an efficient tool for detailed investigations of 
genotype-phenotype relationships because it minimizes con-
founders and improves statistical power while reducing sample 
size21. In this study, we will use the RbG study design to 
assess the functional effects of the three common TMPRSS6 
variants on iron absorption. We expect that this study will pro-
vide new insights into the association between these TMPRSS6 
gene variants and oral iron absorption in a population where 
anaemia prevalence is high. 
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In the introduction the following is stated: ‘We hypothesize that the variant alleles at these SNPs may 
impair iron absorption and may be partially responsible for the disproportionately high anaemia 
prevalence in sub-Saharan Africa.’ This, however, contradicts the lower or at most equal MAF of the 
TMPRSS6 variants in African populations as compared to Caucasian populations. Especially the low 
MAF of rs855791 is important since it has so far shown the strongest inverse association with 
haemoglobin and iron concentrations in Caucasian and Asian populations. It seems to me that the 
conclusion then should be that TMPRSS6 variants are less likely to play a major role in the 
development of anaemia in African populations, unless other variants than the ones under study 
are responsible for such an effect. 
 
Table 1: Since authors already have selected the gene combinations based on numbers available 
in their database of 3000 genotyped individuals, they might as well already indicate the number of 
subjects available for each gene variant combination. 
 
Exclusion criteria: It would seem more appropriate to exclude participants with sickle cell anaemia 
or G6PD deficiency instead of using it as a co-variate in the analysis. However, if this reduces the 
numbers of each genotype combination too much, authors may as well include them while doing 
a retrospective sensitivity analysis. 
 
The primary outcome measure will be the change in serum iron concentration before and five 
hours after a single 400 mg dose of ferrous sulfate iron given orally. This is not the best way to 
measure iron absorption, which would ideally be assessed with a stable isotope method. Past 
studies have shown that change in serum iron concentration cannot be used as a measure of iron 
bioavailability at the individual level. Authors should provide references that back up the validity of 
their approach. 
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most equal MAF of the TMPRSS6 variants in African populations as compared to Caucasian 
populations. Especially the low MAF of rs855791 is important since it has so far shown the 
strongest inverse association with haemoglobin and iron concentrations in Caucasian and 
Asian populations. It seems to me that the conclusion then should be that TMPRSS6 variants 
are less likely to play a major role in the development of anaemia in African populations, 
unless other variants than the ones under study are responsible for such an effect. 
  
Response 1: 
Thank you for this comment. The statement “and may partially be responsible for 
disproportionately high anaemia prevalence in sub-Saharan Africa” has now been changed to 
“these and other genetic variations may contribute to the high anaemia prevalence in sub-
Saharan Africa”. 
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We agree that the MAF of rs855791 is low in African populations (MAF=0.1). In fact, we will 
not be able to address the impact of rs855791 in this study precisely because of this low 
MAF. However, the other two SNPs in this study, rs4820268 and rs3345321, each have a 




Table 1: Since authors already have selected the gene combinations based on numbers 
available in their database of 3000 genotyped individuals, they might as well already 




A column has been added that shows the number of individuals for each genotype group, 
see the table below. 
  
Table 1. Description of the genotype groups as the bases for participant selection 




Number of effect alleles 
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Comment 3: 
Exclusion criteria: It would seem more appropriate to exclude participants with sickle cell 
anaemia or G6PD deficiency instead of using it as a co-variate in the analysis. However, if 
this reduces the numbers of each genotype combination too much, authors may as well 
include them while doing a retrospective sensitivity analysis. 
  
Response 3: 
We do not currently have the G6PD and sick cell carriage status of the participants. Both will 
be determined during this study.    
  
The section describing this now reads “G6PD and sick cell carriage status will be determined 
and individuals carrying these variants will be excluded from the analysis if this will not 
significantly reduce the sample size. Otherwise, a retrospective sensitivity analysis will be 
done to assess the impact of these variants.” (line 206) 
  
Comment 4: 
The primary outcome measure will be the change in serum iron concentration before and 
five hours after a single 400 mg dose of ferrous sulfate iron given orally. This is not the best 
way to measure iron absorption, which would ideally be assessed with a stable isotope 
method. Past studies have shown that change in serum iron concentration cannot be used 
as a measure of iron bioavailability at the individual level. Authors should provide 




We acknowledge that the stable isotope method is heavily favored as a methodology for 
measuring iron absorption. However, we have chosen to use serum iron increase as a proxy 
as a or oral iron absorption based on the work of Nai et al (TMPRSS6 rs855791 modulates 
hepcidin transcription in vitro and serum hepcidin levels in normal individuals. Nai A, Pagani 
A, Silvestri L, Campostrini N, Corbella M, Girelli D, Traglia M, Toniolo D, Camaschella C. 
Blood. 2011 Oct 20;118(16):4459-62. PMID: 21873547) and our own previously published 
work (Cross J, Bradbury R, Fulford A,  Jallow AT,  Prentice AM, Cerami C.  Oral iron acutely 
elevates bacterial growth in human serum. Scientific Reports, 2015 Nov 23;5:16670 PMID: 
26593732 PMCID: PMC4655407). Additionally, we conducted a pilot study in which we 400 
mg ferrous sulfate iron orally to determine the frequency and best time point to have the 






Under study procedures, second paragraph: ‘injestion’ is miss-spelled. 
 Sample size calculation: A type 1 error of 0 seems to be ideal, yet unrealistic. Is this a typo? 
  
Response: 
‘Injestion’ has been corrected to ‘ingestion’ 
“type 1 error of 0’ has been corrected to ‘type 1 error of 0.01’. 
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The study protocol aims to test associations between three variants (rs855791, rs4820268 and 
rs2235321) in TMPRSS6 gene and serum iron concentration after an oral iron supplementation. 
While this study is interesting and the findings are of potential importance, there are some 
concern/suggestions highly recommended to be addressed by the authors. 
 
It has been suggested that a linear model will be fit with genotypes as the outcome, serum iron as 
the predictor, and age, sex, and inflammation status biomarkers as covariates. As it has been well 
established that serum iron levels can be influenced by environmental factors such as smoking 
(Ghio et al. 2008)1, alcohol consumption (Whitfield et al. 2001)2 and also BMI (Shattnawi et al. 
2018)3, the authors should consider collecting these measures and incorporating them into a 
more complex regression model. 
 
Blood collection can be conducted in a detailed plan considering participants’ diet, time of day, 
and so forth. More importantly, the authors could improve serum iron measurement by 
considering a fasting blood test with the pre-defined fasting period such as 12 hours. 
 
In ‘Sample size calculation’ section author claimed that ‘This study size will be able to detect a 12% 
mean decrease in serum iron at five hours after oral iron supplementation between the wild type 
and the variant genotype groups with 90% power and a type 1 error of 0 in this study.’ Please 
elaborate on this sentence and explain how a 12% mean decrease in serum iron was estimated 
(e.g. please state the assumed parameters such as mean and standard deviation of serum iron). 
 
To further understand causal connection between rs855791, rs4820268 and rs2235321 SNPs and 
iron serum level, or iron-deficiency anaemia, the authors will need to conduct molecular 
experiments on mRNAs and proteins to experimentally identify direct effect of the listed SNPs on 
gene expression and then relate the expression level and corresponding genotypes to the trait, in 
this case serum iron level. In addition, a huge accessibility of GWAS, eQTL and pQTL studies 
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enables the authors to perform in-silico analysis to verify their protocol and also hypothesise new 
ideas. Herein, I summarised some of GWAS results relevant to these three SNPs which can be 
furthered investigated in this proposed study. 
 
While rs855791 SNP is a missense variant at TMPRSS6 gene, it is associated with protein levels of 
TFRC (Sun et al. 2018)4 and transcript expression of ALAS2 in blood tissue (Westra et al. 2013)5. 
rs4820268 SNP is a synonymous coding variant of TMPRSS6 gene, but again it is recognised as 
trans-eQTL of ALAS2 in blood tissue (Westra et al. 2013)5. rs2235321 SNP is another synonymous 
coding variant of TMPRSS6 gene and the SNiPA tool reports that it is associated with neither 
complex traits (e.g. iron status biomarkers) nor transcript/protein expression (Arnold et al. 2014)6. 
Altogether, it seems that rs855791 and rs4820268 variants have an impact on ALAS2 expression 
that is most highly expressed in bone marrow tissue (Fagerberg et al. 2014)7 and contributes in 
heme metabolism and iron homeostasis (Barman-Aksözen et al. 2015)8. 
 
Last, it is necessary to make sure that this study will potentially add novel findings into the 
literature in which several studies focused on TMPRSS6 polymorphisms and iron related traits to 
date (Nalado et al. 20199; Sørensen et al. 201910). The authors may consider to focus on 
knowledge gaps and aim to comprehensively relate gene variants to gene expression/activity and 
then serum iron level. Notably, as a functional analysis, population-based differences are not 
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